Skip to main content

Recombinant Human Calsyntenin-2 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 5480-CL

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
5480-CL-050

Key Product Details

Source

NS0

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human Calsyntenin-2 protein
Ser21-Thr834, with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ser21

Predicted Molecular Mass

92.2 kDa

SDS-PAGE

110-120 kDa, reducing condtitions

Activity

Measured by the ability of the immobilized protein to support the adhesion of Neuro-2A mouse neuroblastoma cells.
The ED50 for this effect is 0.7-2.8 μg/mL.

Formulation, Preparation and Storage

5480-CL
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 200 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Calsyntenin-2

Calsyntenin-2, also called Alc-gamma (Alcadein-gamma; gene name CLSTN2) is a 120-135 kDa glycoprotein that is a member of the Alcadein family of cadherin domain‑containing type I transmembrane molecules (1, 2). Mature human Calsyntenin-2 is a 935 amino acid (aa) protein with two extracellular cadherin domains. Proteolytic cleavage by ADAM10 and gamma-secretase generates a 105-110 kDa extracellular domain termed soluble alc-gamma, and a 25 kDa, highly acidic, calcium-binding intracellular domain termed Alc gammaICD (1-3). The soluble alc-gamma portion of human Calsyntenin-2 (aa 21-831) shares 95%, 94%, 96%, 95% and 94% aa identity with mouse, rat, canine, bovine and equine Calsyntenin-2, respectively. A potential isoform variant shows a premature truncation after Gln608. Calsyntenins are predominantly expressed in the ER/Golgi and post-synaptic plasma membranes of neurons (1). While nearly all neurons express Calsyntenin 1, Calsyntenin-2 is mainly found in subpopulations GABAergic  neurons of cortical layers 5 and 6, cerebellum (in Purkinje cells), amygdale (basolateral cells), hippocampus (pyramidal cells and hilus interneurons) and some brain stem neurons (1). Calsyntenin-2 interacts with amyloid precursor protein (APP) through its binding protein, APBA2/X11L, where it is thought to regulate APP cleavage, and likely impacts post-synaptic signaling and gene activation (2, 3). Notably, Alc gammaICD binds APBA1/FE65 and antagonizes amyloid intracellular domain (AICD) gene activation (3). Polymorphisms of the Calsyntenin-2 gene, in combination with polymorphisms of the brain signaling regulator KIBRA, are thought to modulate episodic memory performance (4, 5).

References

  1. Hintsch, G. et al. (2002) Mol. Cell Neurosci. 21:393.
  2. Hata, S. et al. (2009) J. Biol. Chem. 284:36024.
  3. Araki, Y. et al. (2004) J. Biol. Chem. 279:24343.
  4. Jacobsen, L.K. et al. (2009) Biol. Psychiatry 65:671.
  5. Preuschhof, C. et al. (2010) Neuropsychologia 48:402.

Alternate Names

Alcadein-gamma, Calsyntenin2, CLSTN2, CS2, CSTN2

Entrez Gene IDs

64084 (Human); 64085 (Mouse); 171394 (Rat)

Gene Symbol

CLSTN2

UniProt

Additional Calsyntenin-2 Products

Product Documents for Recombinant Human Calsyntenin-2 Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human Calsyntenin-2 Protein, CF

For research use only

Loading...
Loading...
Loading...